Improving the management of ALK-rearranged non-small-cell lung cancer through a mobile application: a physicians-based survey.
Pharmacogenomics
; 24(13): 725-730, 2023 Aug.
Article
em En
| MEDLINE
| ID: mdl-37706248
ABSTRACT
Background:
ALK rearrangements account for around 5% of non-small-cell lung cancers.Aim:
This study surveys physicians on the potential efficacy of a mobile application in improving the management of ALK-rearranged non-small-cell lung cancer, through knowledge, treatment adherence and real-time adverse events reporting. Materials &methods:
A total of 118 physicians from 11 countries in the Middle East participated. Results &conclusion:
Results indicate 94% support for enhancing team communication via an application, and 93% believe real-time adverse events reporting improves the quality of care. Participants found an ALK-rearrangement patient-physicians forum valuable for communication improvement. Motivations for application use included treatment planning (73%), care enhancement (60%) and contributing to publications (40%).
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Médicos
/
Carcinoma Pulmonar de Células não Pequenas
/
Neoplasias Pulmonares
Idioma:
En
Ano de publicação:
2023
Tipo de documento:
Article